BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Igarashi M, Ishizaki Y, Takahashi Y. New antituberculous drugs derived from natural products: current perspectives and issues in antituberculous drug development. J Antibiot (Tokyo) 2017. [PMID: 29089593 DOI: 10.1038/ja.2017.126] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Brown AK, Aljohani AKB, Alsalem FMA, Broadhead JL, Gill JH, Lu Y, Sellars JD. Identification of Substituted Amino Acid Hydrazides as Novel Anti-Tubercular Agents, Using a Scaffold Hopping Approach. Molecules 2020;25:E2387. [PMID: 32455566 DOI: 10.3390/molecules25102387] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Zhou W, Yang B, Zou Y, Rahman K, Cao X, Lei Y, Lai R, Fu ZF, Chen X, Cao G. Screening of Compounds for Anti-tuberculosis Activity, and in vitro and in vivo Evaluation of Potential Candidates. Front Microbiol 2021;12:658637. [PMID: 34276592 DOI: 10.3389/fmicb.2021.658637] [Reference Citation Analysis]
3 Agrawal M, Saraf S, Saraf S, Murty US, Kurundkar SB, Roy D, Joshi P, Sable D, Choudhary YK, Kesharwani P, Alexander A. In-line treatments and clinical initiatives to fight against COVID-19 outbreak. Respir Med 2020;:106192. [PMID: 33199136 DOI: 10.1016/j.rmed.2020.106192] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Moussa AY, Sobhy HA, Eldahshan OA, Singab ANB. Caspicaiene: a new kaurene diterpene with anti-tubercular activity from an Aspergillus endophytic isolate in Gleditsia caspia desf. Nat Prod Res 2020;:1-12. [PMID: 32954811 DOI: 10.1080/14786419.2020.1824222] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
5 Kimura K. Liposidomycin, the first reported nucleoside antibiotic inhibitor of peptidoglycan biosynthesis translocase I: The discovery of liposidomycin and related compounds with a perspective on their application to new antibiotics. J Antibiot 2019;72:877-89. [DOI: 10.1038/s41429-019-0241-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
6 Kazmaier U, Junk L. Recent Developments on the Synthesis and Bioactivity of Ilamycins/Rufomycins and Cyclomarins, Marine Cyclopeptides That Demonstrate Anti-Malaria and Anti-Tuberculosis Activity. Mar Drugs 2021;19:446. [PMID: 34436284 DOI: 10.3390/md19080446] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Mirnejad R, Asadi A, Khoshnood S, Mirzaei H, Heidary M, Fattorini L, Ghodousi A, Darban-Sarokhalil D. Clofazimine: A useful antibiotic for drug-resistant tuberculosis. Biomed Pharmacother 2018;105:1353-9. [PMID: 30021373 DOI: 10.1016/j.biopha.2018.06.023] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
8 Igarashi M. New natural products to meet the antibiotic crisis: a personal journey. J Antibiot (Tokyo) 2019;72:890-8. [PMID: 31462681 DOI: 10.1038/s41429-019-0224-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
9 Grotz E, Tateosian N, Amiano N, Cagel M, Bernabeu E, Chiappetta DA, Moretton MA. Nanotechnology in Tuberculosis: State of the Art and the Challenges Ahead. Pharm Res 2018;35. [DOI: 10.1007/s11095-018-2497-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
10 Luo X, Lin Y, Lu Y, Zhou X, Liu Y. Peptides and polyketides isolated from the marine sponge-derived fungus Aspergillus terreus SCSIO 41008. Chinese Journal of Natural Medicines 2019;17:149-54. [DOI: 10.1016/s1875-5364(19)30017-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
11 Halicki PCB, Ferreira LA, De Moura KCG, Carneiro PF, Del Rio KP, Carvalho TDSC, Pinto MDCFR, da Silva PEA, Ramos DF. Naphthoquinone Derivatives as Scaffold to Develop New Drugs for Tuberculosis Treatment. Front Microbiol 2018;9:673. [PMID: 29686657 DOI: 10.3389/fmicb.2018.00673] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.8] [Reference Citation Analysis]